Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Anti-inflammatory Effect of Dilmapimod in COPD
NCT00144859Phase 2Completed
- Sponsor
- GSK
- Start
- Jul 2005
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Dilmapimod with Placebo (2 arms). Primary endpoints: Incidence of elevated liver function tests at 28 days and Serum concentration c-reactive protein at 28 days. Started Jul 2005; status: completed.
02
Drugs
dilmapimod
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00144859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00144859.